Torniquete aórtico y de unión abdominal estabilizado (AAJT-S)

What makes the AAJT-S different from the JETT and SAM Junctional Tourniquet?

The AAJT-S is the only FDA-cleared hemorrhage control device indicated for external abdominal aortic compression — a capability the JETT and SAM Junctional Tourniquet do not have. All three devices address inguinal and axillary junctional hemorrhage, but only the AAJT-S can be placed at the aortic bifurcation (lower abdomen) to achieve Zone 3 REBOA-equivalent compression without vascular access. This makes it the only non-invasive tool capable of addressing Non-Compressible Torso Hemorrhage (NCTH). It is also the only device cleared for all four indications simultaneously: abdominal, inguinal, axillary, and pelvic fracture stabilization.

Is the AAJT-S CoTCCC-recommended?

The AAJT-S is not currently on the CoTCCC junctional tourniquet recommendation list as of 2025. CoTCCC formally recommends the JETT and SAM Junctional Tourniquet as the primary junctional devices. The AAJT-S was considered in the original 2013 CoTCCC junctional tourniquet review but was designated as a device of last resort for abdominal placement due to its 1-hour abdominal application limit and relative contraindication in penetrating abdominal trauma — injuries common in conjunction with junctional hemorrhage. For inguinal and axillary use, it has a broader indication set than any single competing device.

How is the pressure indicator used when applying the AAJT-S?

The AAJT-S includes a built-in pressure gauge with a green zone indicator calibrated to approximately 250 mmHg. The operator inflates the hand pump bulb until the gauge indicator reaches green, confirming sufficient arterial compression pressure. A built-in 300 mmHg pressure relief valve automatically prevents over-inflation — the bladder will not exceed safe pressure regardless of how many additional pump strokes are applied. This 'inflate to green' protocol eliminates the operator pressure judgment variability that affects manual compression and non-gauged devices.

Can the AAJT-S be used for Zone 3 REBOA?

Yes, but as a non-invasive external adjunct, not a replacement for interventional REBOA. A 2024 study in the Journal of Special Operations Medicine demonstrated that AAJT-S abdominal placement provides clinically significant Zone 3 aortic and vena cava compression, reducing blood flow distal to the device and improving proximal perfusion to the thorax and brain. Unlike invasive REBOA — which requires femoral arterial access and a trained operator — the AAJT-S can be applied by any trained first responder in under 2 minutes with minimal equipment. It is most valuable as a bridge to surgical or interventional care when REBOA is unavailable.

How long can the AAJT-S remain in place, and what are the risks of prolonged use?

For abdominal (aortic) placement, the manufacturer recommends a maximum application time of 1 hour due to the risk of ischemia-reperfusion injury to abdominal organs and spinal cord distal to the device. Animal studies at 90 minutes showed developing paraplegia and colonic necrosis; the 60-minute group had no lasting side effects. For inguinal and axillary placements, up to 4 hours is recommended, consistent with guidance for other junctional tourniquets. All placements require continuous monitoring for hemorrhage control, patient tolerance, and hemodynamic response. Application time must be documented immediately.